Treatment of osteoporosis in men

被引：69

作者：

Kaufman, J. -M. ^{[1
,2
]}

Reginster, J. -Y. ^{[3
]}

Boonen, S. ^{[4
,5
]}

Brandi, M. L. ^{[6
]}

Cooper, C. ^{[7
,8
]}

Dere, W. ^{[9
]}

Devogelaer, J. -P. ^{[10
]}

Diez-Perez, A. ^{[11
]}

Kanis, J. A. ^{[12
]}

McCloskey, E. ^{[13
,14
]}

Mitlak, B. ^{[15
]}

Orwoll, E. ^{[16
]}

Ringe, J. D. ^{[17
]}

Weryha, G. ^{[18
]}

Rizzoli, R. ^{[19
,20
]}

机构：

[1] Ghent Univ Hosp, Dept Endocrinol, B-9000 Ghent, Belgium

[2] Ghent Univ Hosp, Unit Osteoporosis & Metab Bone Dis, B-9000 Ghent, Belgium

[3] CHU Ctr Ville, Head Bone & Cartilage Metab Unit, Liege, Belgium

[4] Univ Louvain, Div Gerontol & Geriatr, Louvain, Belgium

[5] Univ Louvain, Dept Expt Med, Ctr Musculoskeletal Res, Louvain, Belgium

[6] Univ Florence, Dept Internal Med, Unit Metab Bone Dis, Florence, Italy

[7] Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England

[8] Univ Oxford, Inst Musculoskeletal Sci, NIHR Musculoskeletal Biomed Res Unit, Oxford, England

[9] Amgen Inc, Uxbridge, Middx, England

[10] Catholic Univ Louvain, Arthrit Unit UCL5390, B-1200 Brussels, Belgium

[11] Univ Autonoma Barcelona, Hosp del Mar, IMIM, E-08193 Barcelona, Spain

[12] Univ Sheffield, Sch Med, Ctr Metab Bone Dis, WHO Collaborating Ctr, Sheffield, S Yorkshire, England

[13] Univ Sheffield, Acad Unit Bone Metab, Sheffield, S Yorkshire, England

[14] Sheffield Teaching Hosp NHS Trust, NIHR Musculoskeletal Biomed Res Unit, Sheffield, S Yorkshire, England

[15] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA

[16] Oregon Hlth & Sci Univ, Dept Med, Bone & Mineral Unit, Portland, OR 97201 USA

[17] Univ Cologne, Klinikum Leverkusen, W German Osteoporosis Ctr WOZ, Cologne, Germany

[18] CHU Nancy, Dept Endocrinol, Vandoeuvre Les Nancy, France

[19] Univ Hosp Geneva, Serv Bone Dis, CH-1211 Geneva 14, Switzerland

[20] Fac Med, CH-1211 Geneva 14, Switzerland

来源：

BONE | 2013年 / 53卷 / 01期

关键词：

Bone mineral density; Fracture risk; Gonadal hormone status; Treatment; T-score; BONE-MINERAL DENSITY; PARATHYROID-HORMONE; 1-34; YEARLY ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; FRACTURE RISK; HIP FRACTURE; ELDERLY-MEN; RANDOMIZED-TRIAL; STRONTIUM RANELATE; OLDER MEN;

D O I：

10.1016/j.bone.2012.11.018

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Aspects of osteoporosis in men, such as screening and identification strategies, definitions of diagnosis and intervention thresholds, and treatment options (both approved and in the pipeline) are discussed. Introduction: Awareness of osteoporosis in men is improving, although it remains under-diagnosed and under-treated. A European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) workshop was convened to discuss osteoporosis in men and to provide a report by a panel of experts (the authors). Methods: A debate with an expert panel on preselected topics was conducted. Results and conclusions: Although additional fracture data are needed to endorse the clinical care of osteoporosis in men, consensus views were reached on diagnostic criteria and intervention thresholds. Empirical data in men display similarities with data acquired in women, despite pathophysiological differences, which may not be clinically relevant. Men should receive treatment at a similar 10-year fracture probability as in women. The design of mixed studies may reduce the lag between comparable treatments for osteoporosis in women becoming available in men. (C) 2012 Elsevier Inc. All rights reserved.

引用

页码：134 / 144

页数：11

共 110 条

[1]

Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham study [J].

Amin, S ;

Zhang, YQ ;

Felson, DT ;

Sawin, CT ;

Hannan, MT ;

Wilson, PWF ;

Kiel, DP .

AMERICAN JOURNAL OF MEDICINE, 2006, 119 (05) :426-433

[2]

Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the framingham study [J].

Amin, S ;

Zhang, YQ ;

Sawin, DT ;

Evans, SR ;

Hannan, MT ;

Kiel, DP ;

Wilson, PWF ;

Felson, DT .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (12) :951-963

[3]

[Anonymous], WHO 1998

[4]

Minireview:: Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton [J].

Baron, Roland ;

Rawadi, Georges .

ENDOCRINOLOGY, 2007, 148 (06) :2635-2643

[5]

Bauer DC, 2009, J BONE MINER RES, V24, P2032, DOI [10.1359/JBMR.090526, 10.1359/jbmr.090526]

[6]

Osteoporosis in men [J].

Bilezikian, JP .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) :3431-3434

[7]

Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].

Black, Dennis M. ;

Schwartz, Ann V. ;

Ensrud, Kristine E. ;

Cauley, Jane A. ;

Levis, Silvina ;

Quandt, Sara A. ;

Satterfield, Suzanne ;

Wallace, Robert B. ;

Bauer, Douglas C. ;

Palermo, Lisa ;

Wehren, Lois E. ;

Lombardi, Antonio ;

Santora, Arthur C. ;

Cummings, Steven R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938

[8]

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].

Black, DM ;

Greenspan, SL ;

Ensrud, KE ;

Palermo, L ;

McGowan, JA ;

Lang, TF ;

Garnero, P ;

Bouxsein, ML ;

Bilezikian, JP ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215

[9]

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis [J].

Black, DM ;

Bilezikian, JP ;

Ensrud, KE ;

Greenspan, SL ;

Palermo, L ;

Hue, T ;

Lang, TF ;

McGowan, JA ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :555-565

[10]

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

← 1 2 3 4 5 6 7 8 9 10 →